Compare Stocks: SGMO, INO, ENGN, and AADI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AADI Aadi Bioscience	$4.62 -5.1%	$4.26	$1.21 ▼ $3.81	$114.10M	0.68	261,100 shs	100,065 shs
ENGN enGene	$1.83 -4.5%	$1.81	$1.40 ▼ $12.25	$122.25M	-0.28	708,781 shs	447,088 shs
INO Inovio Pharmaceuticals	$1.29 +2.4%	$1.05	$0.56 ▼ $2.98	$133.38M	1.52	5.45 million shs	1.70 million shs
SGMO Sangamo Therapeutics	$0.07	$0.08	$0.06 ▼ $0.77	$30.66M	1.3	8.10 million shs	N/A

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AADI Aadi Bioscience	-5.13%	-2.33%	+26.23%	-2.12%	+155.25%
ENGN enGene	0.00%	+2.53%	+3.69%	-1.35%	-57.95%
INO Inovio Pharmaceuticals	0.00%	+9.32%	+96.65%	-1.53%	-47.56%
SGMO Sangamo Therapeutics	0.00%	0.00%	0.00%	-66.01%	-86.26%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AADI Aadi Bioscience	$4.62 -5.1%	$4.26	$1.21 ▼ $3.81	$114.10M	0.68	261,100 shs	100,065 shs
ENGN enGene	$1.83 -4.5%	$1.81	$1.40 ▼ $12.25	$122.25M	-0.28	708,781 shs	447,088 shs
INO Inovio Pharmaceuticals	$1.29 +2.4%	$1.05	$0.56 ▼ $2.98	$133.38M	1.52	5.45 million shs	1.70 million shs
SGMO Sangamo Therapeutics	$0.07	$0.08	$0.06 ▼ $0.77	$30.66M	1.3	8.10 million shs	N/A

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AADI Aadi Bioscience	-5.13%	-2.33%	+26.23%	-2.12%	+155.25%
ENGN enGene	0.00%	+2.53%	+3.69%	-1.35%	-57.95%
INO Inovio Pharmaceuticals	0.00%	+9.32%	+96.65%	-1.53%	-47.56%
SGMO Sangamo Therapeutics	0.00%	0.00%	0.00%	-66.01%	-86.26%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AADI Aadi Bioscience	0.00	N/A	N/A	N/A
ENGN enGene	2.14	Hold	$11.05	505.23% Upside
INO Inovio Pharmaceuticals	2.75	Moderate Buy	$3.17	145.48% Upside
SGMO Sangamo Therapeutics	1.75	Reduce	$5.50	7,332.43% Upside

Current Analyst Ratings Breakdown

Latest SGMO, INO, ENGN, and AADI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	INO Inovio Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	INO Inovio Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/13/2026	INO Inovio Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Positive	$1.80 ➝ $3.00
8/12/2026	ENGN enGene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/12/2026	INO Inovio Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/3/2026	INO Inovio Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$4.00
7/29/2026	INO Inovio Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/1/2026	INO Inovio Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/18/2026	ENGN enGene	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Equal Weight ➝ Underweight	$3.00
6/16/2026	INO Inovio Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/16/2026	ENGN enGene	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$6.00 ➝ $4.00

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AADI Aadi Bioscience	$25.07M	4.55	N/A	N/A	$4.29 per share	1.08
ENGN enGene	N/A	N/A	N/A	N/A	$2.60 per share	N/A
INO Inovio Pharmaceuticals	$60K	2,223.10	N/A	N/A	$0.04 per share	32.25
SGMO Sangamo Therapeutics	$39.55M	0.78	N/A	N/A	($0.04) per share	-1.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AADI Aadi Bioscience	-$65.76M	-$2.35	N/A	N/A	N/A	-246.06%	-71.87%	-57.28%	N/A
ENGN enGene	-$117.30M	-$2.17	N/A	N/A	N/A	N/A	-56.06%	-45.64%	9/14/2026 (Estimated)
INO Inovio Pharmaceuticals	-$84.95M	-$0.91	N/A	N/A	N/A	N/A	-669.94%	-73.97%	11/10/2026 (Estimated)
SGMO Sangamo Therapeutics	-$122.93M	-$0.38	N/A	N/A	N/A	-310.81%	-2,662.06%	-132.12%	N/A

Latest SGMO, INO, ENGN, and AADI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/14/2026	Q3 2026	ENGN enGene	-$0.47	N/A	N/A	N/A	N/A	N/A
8/12/2026	Q2 2026	INO Inovio Pharmaceuticals	-$0.2167	-$0.07	+$0.1467	-$0.07	$0.53 million	N/A
6/15/2026	Q2 2026	ENGN enGene	-$0.48	-$0.43	+$0.05	-$0.43	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AADI Aadi Bioscience	N/A	N/A	N/A	N/A	N/A
ENGN enGene	$1.58	86.63%	N/A	N/A	N/A
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SGMO Sangamo Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AADI Aadi Bioscience	N/A	4.89	4.54
ENGN enGene	0.10	12.57	12.57
INO Inovio Pharmaceuticals	N/A	1.00	1.00
SGMO Sangamo Therapeutics	N/A	0.84	0.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AADI Aadi Bioscience	52.08%
ENGN enGene	64.16%
INO Inovio Pharmaceuticals	26.79%
SGMO Sangamo Therapeutics	56.92%

Insider Ownership

Company	Insider Ownership
AADI Aadi Bioscience	37.30%
ENGN enGene	10.50%
INO Inovio Pharmaceuticals	1.70%
SGMO Sangamo Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AADI Aadi Bioscience	40	24.70 million	15.49 million	No Data
ENGN enGene	31	66.99 million	59.95 million	N/A
INO Inovio Pharmaceuticals	320	103.40 million	101.64 million	Optionable
SGMO Sangamo Therapeutics	480	414.29 million	397.29 million	Optionable

SGMO, INO, ENGN, and AADI Headlines

Recent News About These Companies

Sangamo Therapeutics Advances Bankruptcy Asset Sale Process

July 20, 2026 | tipranks.com

Sangamo Therapeutics Inc SGMO

July 7, 2026 | morningstar.comM

Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas

June 24, 2026 | markets.businessinsider.com

Sangamo falls after Chapter 11 bankruptcy filing; Eli Lilly and Astellas to acquire key assets

June 24, 2026 | seekingalpha.com

Sangamo Therapeutics files for Chapter 11 bankruptcy

June 24, 2026 | msn.com

Sangamo Therapeutics Initiates Chapter 11 and Asset Sales

June 23, 2026 | tipranks.com

Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders

June 8, 2026 | globenewswire.com

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2026 Earnings Call Transcript

May 16, 2026 | insidermonkey.com

Sangamo Therapeutics Inc (SGMO) Q1 2026 Earnings Call Highlights: Progress Amidst Financial ...

May 16, 2026 | finance.yahoo.com

Sangamo Therapeutics Reports No Unregistered Equity Sales or Share Repurchases for the Period

May 16, 2026 | tipranks.com

Sangamo Therapeutics, Inc. (SGMO) Q1 2026 Earnings Call Transcript

May 14, 2026 | seekingalpha.com

Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates

May 14, 2026 | zacks.com

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results

May 14, 2026 | globenewswire.com

Sangamo Therapeutics Announces First Quarter 2026 Earnings Call

May 11, 2026 | markets.businessinsider.com

Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market

May 5, 2026 | finanznachrichten.de

Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)

April 30, 2026 | globenewswire.com

Sangamo Therapeutics (SGMO) Nasdaq delisting shifts stock to OTCQB market

April 29, 2026 | finance.yahoo.com

Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market

April 29, 2026 | globenewswire.com

Sangamo Therapeutics (NASDAQ:SGMO) Insider Sells $17,456.75 in Stock

April 24, 2026 | insidertrades.com

Sangamo Therapeutics Faces Rising Trade Policy Risks, Higher Costs and Global Growth Uncertainty

April 1, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SGMO, INO, ENGN, and AADI Company Descriptions

Aadi Bioscience NASDAQ:AADI

$4.62 -0.25 (-5.13%)

As of 08/28/2026

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

enGene NASDAQ:ENGN

$1.82 -0.09 (-4.45%)

As of 08/28/2026 04:00 PM Eastern

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Inovio Pharmaceuticals NASDAQ:INO

$1.29 +0.03 (+2.38%)

As of 08/28/2026 04:00 PM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Sangamo Therapeutics NASDAQ:SGMO

$0.07 0.00 (0.00%)

As of 08/28/2026

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SGMO, INO, ENGN, and AADI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SGMO, INO, ENGN, and AADI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SGMO, INO, ENGN, and AADI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SGMO, INO, ENGN, and AADI Company Descriptions

Aadi Bioscience NASDAQ:AADI

enGene NASDAQ:ENGN

Inovio Pharmaceuticals NASDAQ:INO

Sangamo Therapeutics NASDAQ:SGMO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SGMO, INO, ENGN, and AADI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SGMO, INO, ENGN, and AADI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SGMO, INO, ENGN, and AADI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SGMO, INO, ENGN, and AADI Company Descriptions

Aadi Bioscience NASDAQ:AADI

enGene NASDAQ:ENGN

Inovio Pharmaceuticals NASDAQ:INO

Sangamo Therapeutics NASDAQ:SGMO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools